Inviragen, Duke-NUS sign MOU
Inviragen is a developer of vaccines to protect against infectious diseases worldwide. The MOU calls for the formation of a management committee co-chaired by Casey and Dan Stinchcomb,
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
Earlier, Takeda collaborated with its wholly-owned subsidiaries Takeda San Francisco, Millennium Pharmaceuticals, Takeda Bio Development Center and Chemistry, Manufacturing and Controls (CMC) Center to commercialize new drug candidate